VEGFA and renal cell carcinoma: Our results indicated that THZ1 dose-dependently suppressed VEGF secretion and expression in Caki-2 (Figure 5A) and 786-O cells (Figure 5B) after 24 and 48 h of treatment, indicating the potential application of THZ1 for antiangiogenic therapy of RCC.